CD8A and neoplasm: Disease stabilization (>12 weeks) and tumor shrinkage (2%–69%) were seen across several tumor types, including melanoma, prostate cancer, bladder cancer, breast cancer, clear cell renal carcinoma, NSCLC, and HNSCC.19 In addition, a phase II neoadjuvant prostate cancer trial (NCT02923180) demonstrated that CD8 T-cell density in prostatectomy samples was significantly higher in enoblituzumab-treated patients compared with age-matched and stage-matched untreated prostatectomy controls.20